Press Release
Source: Viral Genetics, Inc.

Dutton Associates Announces Investment Opinion: Viral Genetics Rating At Neutral In Update Coverage By Dutton Associates.

ROSEVILLE, Calif.--(BUSINESS WIRE)--Mar 12, 2008 -- Dutton Associates updates its coverage of Viral Genetics (Pink Sheets: VRAL - News) with a Neutral rating. The 10-page report by Dutton senior analyst Wayne Lottinville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

Viral Genetics is a development-stage biotechnology company with one drug candidate in development. The preliminary results from a study which involved 137 patients suggest that the Company may have identified a potential anti-HIV drug that acts differently from the current therapies and thus may provide a significant success rate in combating the virus. The recent announcement of progress made in identifying the underlying mechanisms of the drug adds to the Company’s case. Phase 3 clinical trials have been completed in South Africa, which should allow the Company to begin commercializing VGV-1 there fairly soon. However, Viral Genetics is in the preclinical stage in the U.S. and thus is far from realizing revenues (if any) in the U.S. and Europe. The Company has no cash, and historically the chances for a preclinical-stage drug to reach commercialization have been minuscule; also, it takes years for a drug to go through all stages of development, clinical trials and approvals in the U.S. Although we find Viral Genetics’ drug development program promising, keeping in mind the high uncertainty regarding the future of the drug development due to lack of funds and long development horizon in the U.S. we cannot rate the stock a buy until the Company gains a firmer financial footing.

About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 30 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. The Firm does not accept any equity compensation. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing on 10/10/2006. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

For additional information, please contact Viral Genetics at 626-334-5310.

Contact:
For additional information, please contact:
Viral Genetics
626-334-5310

Source: Viral Genetics, Inc.

Click here to return to our Press Release selection page.

Press Releases

Media Kits

Media Inquiries

News Subscription Service